RU2014121304A - Ингибирование экспрессии вирусных генов - Google Patents
Ингибирование экспрессии вирусных генов Download PDFInfo
- Publication number
- RU2014121304A RU2014121304A RU2014121304/10A RU2014121304A RU2014121304A RU 2014121304 A RU2014121304 A RU 2014121304A RU 2014121304/10 A RU2014121304/10 A RU 2014121304/10A RU 2014121304 A RU2014121304 A RU 2014121304A RU 2014121304 A RU2014121304 A RU 2014121304A
- Authority
- RU
- Russia
- Prior art keywords
- nucleic acid
- acid molecule
- molecule according
- virus
- paragraphs
- Prior art date
Links
- 108700005077 Viral Genes Proteins 0.000 title 1
- 230000005764 inhibitory process Effects 0.000 title 1
- 150000007523 nucleic acids Chemical class 0.000 claims abstract 35
- 108020004707 nucleic acids Proteins 0.000 claims abstract 33
- 102000039446 nucleic acids Human genes 0.000 claims abstract 33
- 108020004459 Small interfering RNA Proteins 0.000 claims abstract 14
- 230000000692 anti-sense effect Effects 0.000 claims abstract 14
- 239000004055 small Interfering RNA Substances 0.000 claims abstract 14
- 241000700605 Viruses Species 0.000 claims abstract 11
- 239000002773 nucleotide Substances 0.000 claims abstract 8
- 125000003729 nucleotide group Chemical group 0.000 claims abstract 8
- 108091081021 Sense strand Proteins 0.000 claims abstract 6
- 208000002672 hepatitis B Diseases 0.000 claims abstract 6
- 239000002777 nucleoside Substances 0.000 claims abstract 6
- 150000003833 nucleoside derivatives Chemical class 0.000 claims abstract 6
- -1 cytidine phosphoramidite Chemical class 0.000 claims abstract 5
- 208000006454 hepatitis Diseases 0.000 claims abstract 5
- 231100000283 hepatitis Toxicity 0.000 claims abstract 5
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 claims abstract 2
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 claims abstract 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 claims abstract 2
- FMTMKSBQVRKFLG-MQJQZHHKSA-N [(2R,3R,4R,5R)-5-(6-aminopurin-9-yl)-4-[3-(diaminomethylideneamino)propoxy]-3-hydroxyoxolan-2-yl]methoxyphosphonamidous acid Chemical compound NP(O)OC[C@H]1O[C@H]([C@H](OCCCNC(N)=N)[C@@H]1O)n1cnc2c(N)ncnc12 FMTMKSBQVRKFLG-MQJQZHHKSA-N 0.000 claims abstract 2
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 claims abstract 2
- 230000000295 complement effect Effects 0.000 claims abstract 2
- 230000030279 gene silencing Effects 0.000 claims abstract 2
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 claims abstract 2
- 229940045145 uridine Drugs 0.000 claims abstract 2
- 230000029812 viral genome replication Effects 0.000 claims abstract 2
- 238000000034 method Methods 0.000 claims 8
- 208000036142 Viral infection Diseases 0.000 claims 6
- 230000009385 viral infection Effects 0.000 claims 6
- 208000015181 infectious disease Diseases 0.000 claims 3
- 241000700721 Hepatitis B virus Species 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 210000004748 cultured cell Anatomy 0.000 claims 1
- 230000016396 cytokine production Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- MUJAPBLBQIDQSQ-CCUFREDKSA-N [(2r,3s,4r,5r)-5-(2-amino-6-oxo-3h-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxyphosphonamidous acid Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)N)O[C@H]1N1C(N=C(N)NC2=O)=C2N=C1 MUJAPBLBQIDQSQ-CCUFREDKSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3527—Other alkyl chain
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ZA2011/07890 | 2011-10-28 | ||
| ZA201107890 | 2011-10-28 | ||
| PCT/IB2012/055915 WO2013061295A1 (en) | 2011-10-28 | 2012-10-26 | Inhibition of viral gene expression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2014121304A true RU2014121304A (ru) | 2015-12-10 |
Family
ID=47326248
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014121304/10A RU2014121304A (ru) | 2011-10-28 | 2012-10-26 | Ингибирование экспрессии вирусных генов |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20140350080A1 (enExample) |
| EP (1) | EP2771466A1 (enExample) |
| CN (1) | CN104011209A (enExample) |
| AP (1) | AP2014007650A0 (enExample) |
| BR (1) | BR112014010134A2 (enExample) |
| CA (1) | CA2853609A1 (enExample) |
| IN (1) | IN2014CN03921A (enExample) |
| RU (1) | RU2014121304A (enExample) |
| WO (1) | WO2013061295A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104603271B (zh) | 2012-07-03 | 2019-07-19 | 马林生物科技有限公司 | 用于治疗肌肉萎缩症患者的寡核苷酸 |
| EP3315608B1 (en) * | 2015-06-26 | 2020-09-16 | Suzhou Ribo Life Science Co., Ltd. | Sirna, pharmaceutical composition and conjugate which contain sirna, and uses thereof |
| JP6924744B2 (ja) | 2015-07-17 | 2021-08-25 | アークトゥラス・セラピューティクス・インコーポレイテッドＡｒｃｔｕｒｕｓ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | Ｂ型肝炎ウイルスに対する組成物および薬剤ならびにその使用 |
| US20170137821A1 (en) | 2015-07-17 | 2017-05-18 | Arcturus Therapeutics, Inc. | Molecules and agents for treating hepatitis b virus |
| EP3643706B1 (en) * | 2017-06-16 | 2023-11-15 | Eisai R&D Management Co., Ltd. | Modified nucleic acid monomers and oligonucleic acid analogues, with high biological stability and target gene silencing activity, for use in therapy and diagnosis of cancer and viral diseases |
| HRP20250277T1 (hr) | 2017-12-01 | 2025-05-09 | Suzhou Ribo Life Science Co., Ltd. | Dvolančani oligonukleotid, sastav i konjugat koji sadrži dvolančani oligonukleotid, postupak njihove pripreme i upotreba |
| JP7360716B2 (ja) * | 2017-12-01 | 2023-10-13 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、当該核酸を含む組成物および複合体ならびに調製方法と使用 |
| EP3873488B1 (en) * | 2018-10-31 | 2025-03-19 | The University of Sydney | Pharmaceutical compositions for use in treating an hbv or hdv infection |
| JP7507495B2 (ja) | 2018-12-28 | 2024-06-28 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用 |
| CN113286888B (zh) | 2019-05-22 | 2023-12-22 | 苏州瑞博生物技术股份有限公司 | 核酸、药物组合物与缀合物及制备方法和用途 |
| JP7610848B2 (ja) | 2019-05-22 | 2025-01-09 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、薬物組成物及び複合体ならびに調製方法と使用 |
| CN113227376B (zh) | 2019-05-22 | 2024-04-09 | 苏州瑞博生物技术股份有限公司 | 核酸、药物组合物与缀合物及制备方法和用途 |
| CN113795582B (zh) | 2019-05-24 | 2024-05-24 | 苏州瑞博生物技术股份有限公司 | 核酸、药物组合物与缀合物及制备方法和用途 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1814614A (zh) * | 2005-02-06 | 2006-08-09 | 中国人民解放军军事医学科学院毒物药物研究所 | 核酸、肽核酸衍生物及它们的用途 |
| US20100209491A1 (en) * | 2007-09-17 | 2010-08-19 | Mogam Biotechnology Research Institute | Method for enhancing serum stability and lowering immune response of sirna down-regulating gene expression of hbv or hcv |
-
2012
- 2012-10-26 CA CA2853609A patent/CA2853609A1/en not_active Abandoned
- 2012-10-26 EP EP12798850.9A patent/EP2771466A1/en not_active Withdrawn
- 2012-10-26 RU RU2014121304/10A patent/RU2014121304A/ru not_active Application Discontinuation
- 2012-10-26 US US14/354,180 patent/US20140350080A1/en not_active Abandoned
- 2012-10-26 CN CN201280053081.0A patent/CN104011209A/zh active Pending
- 2012-10-26 WO PCT/IB2012/055915 patent/WO2013061295A1/en not_active Ceased
- 2012-10-26 AP AP2014007650A patent/AP2014007650A0/xx unknown
- 2012-10-26 BR BR112014010134A patent/BR112014010134A2/pt not_active IP Right Cessation
- 2012-10-26 IN IN3921CHN2014 patent/IN2014CN03921A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2853609A1 (en) | 2013-05-02 |
| BR112014010134A2 (pt) | 2019-09-24 |
| AP2014007650A0 (en) | 2014-05-31 |
| US20140350080A1 (en) | 2014-11-27 |
| WO2013061295A1 (en) | 2013-05-02 |
| EP2771466A1 (en) | 2014-09-03 |
| CN104011209A (zh) | 2014-08-27 |
| IN2014CN03921A (enExample) | 2015-09-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7798836B2 (ja) | Ｂ型肝炎感染の治療用のＰＡＰＤ５及びＰＡＰＤ７ ｍＲＮＡを低減させるための核酸分子 | |
| ES2651308T3 (es) | Inhibidores antisentido de HBV | |
| EP4455285A3 (en) | Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof | |
| RU2019100094A (ru) | МОЛЕКУЛЫ НУКЛЕИНОВЫХ КИСЛОТ ДЛЯ УМЕНЬШЕНИЯ УРОВНЯ мРНК PAPD5 ИЛИ PAPD7 ДЛЯ ЛЕЧЕНИЯ ИНФЕКЦИОННОГО ГЕПАТИТА В | |
| JP2022511550A5 (enExample) | ||
| WO2018209848A1 (zh) | 抑制HBV的siRNA分子及其应用 | |
| US20110055965A1 (en) | Cycle single-stranded nucleic acid complex and method for producing the same | |
| CN112055749A (zh) | Fubp1抑制剂用于治疗乙型肝炎病毒感染的用途 | |
| JP7634542B2 (ja) | Ｂ型肝炎ウイルス感染症を処置するためのｓｅｐｔ９阻害剤の使用 | |
| JP2025166835A (ja) | Ｂ型肝炎ウイルス感染を処置するためのｓｃａｍｐ３阻害剤の使用 | |
| TWI791868B (zh) | 調節rtel1表現之寡核苷酸 | |
| JP2025094072A (ja) | Ｂ型肝炎ウイルス感染を処置するためのｃｏｐｓ３阻害剤の使用 | |
| CN114867856A (zh) | Saraf抑制剂用于治疗乙型肝炎病毒感染的用途 | |
| JP2022531580A (ja) | ベクターでの使用のためのマルチプレックス化ｓｈＲＮＡ | |
| CN114829601A (zh) | Sbds抑制剂用于治疗乙型肝炎病毒感染的用途 | |
| Ivashchenko et al. | BIOINFORMATIC APPROACHES IN STUDY OF MIRNA INTERACTION WITH THE GENOMES OF THE SARS-COV-2, MERS-COV, AND SARS-COV | |
| HK40117347A (en) | Combination of oligonucleotides for modulating rtel1 and fubp1 | |
| WO2024228398A1 (ja) | グアニン四重鎖構造を誘導するための核酸剤 | |
| HK40078456A (en) | Use of sbds inhibitors for treating hepatitis b virus infection | |
| CN119095603A (zh) | 用于调节rtel1和fubp1的寡核苷酸的组合 | |
| HK40077333A (en) | Use of saraf inhibitors for treating hepatitis b virus infection | |
| HK40078459A (en) | Use of scamp3 inhibitors for treating hepatitis b virus infection | |
| HK40071185A (en) | Use of sept9 inhibitors for treating hepatitis b virus infection | |
| NZ750390A (en) | Rnai agents for hepatitis b virus infection | |
| JP2011160674A (ja) | 新規アンチセンスｒｎａステム・ループ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20151027 |